- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07225946
Uno studio su Pasritamig con Docetaxel rispetto a Docetaxel in partecipanti con carcinoma prostatico metastatico resistente alla castrazione (KLK2-PASenger)
Uno studio di fase 3 randomizzato, in aperto su Pasritamig (JNJ-78278343), un agente di reindirizzamento delle cellule T che mira alla callicreina 2 umana, con docetaxel versus docetaxel per il cancro alla prostata metastatico resistente alla castrazione
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Heidelberg, Australia, 3084
- Reclutamento
- Warringal Private Hospital
-
Kurralta Park, Australia, 5037
- Reclutamento
- Icon Cancer Centre Kurralta Park
-
Melbourne, Australia, 3000
- Reclutamento
- Peter MacCallum Cancer Centre
-
Wahroonga, Australia, 2076
- Reclutamento
- Sydney Adventist Hospital
-
Woolloongabba, Australia, 4102
- Reclutamento
- Princess Alexandra Hospital
-
-
-
-
-
Aalst, Belgio, 9300
- Reclutamento
- AZORG campus Aalst Moorselbaan
-
Antwerp, Belgio, 2610
- Reclutamento
- ZAS Augustinus
-
Ghent, Belgio, 9000
- Reclutamento
- AZ Maria Middelares
-
La Louvière, Belgio, 7100
- Reclutamento
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège, Belgio, 4000
- Reclutamento
- CHC MontLegia
-
-
-
-
-
Bauru, Brasile, 17033-495
- Reclutamento
- NAIC Nair Antunes Instituto do Cancer
-
Natal, Brasile, 59062 000
- Reclutamento
- Liga Norte Riograndense Contra O Cancer
-
Santa Cruz do Sul, Brasile, 96835-100
- Reclutamento
- Hospital Ana Nery Santa Cruz do Sul
-
Santo André, Brasile, 09060 870
- Reclutamento
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasile, 01243 020
- Reclutamento
- Hospital Samaritano de Sao Paulo
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z4E6
- Reclutamento
- British Columbia Cancer Agency
-
Victoria, British Columbia, Canada, V8R 6V5
- Reclutamento
- British Columbia Cancer Agency Vancouver Island Centre
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Reclutamento
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Canada, M5G 2C4
- Reclutamento
- Princess Margaret Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0A9
- Reclutamento
- Centre de Recherche du CHUM
-
Québec, Quebec, Canada, G1R 2J6
- Reclutamento
- CHU de Quebec Universite Laval
-
-
-
-
-
Beijing, Cina, 100142
- Reclutamento
- Beijing Cancer Hospital
-
Beijing, Cina, 100034
- Reclutamento
- Peking University First Hospital
-
Beijing, Cina, 101100
- Reclutamento
- Beijing Luhe Hospital, Capital Medical University
-
Chengdu, Cina, 610014
- Reclutamento
- The Third People's Hospital of Chengdu
-
Chengdu, Cina, 610041
- Reclutamento
- West China Hospital Sichuan University
-
Chongqing, Cina, 400030
- Reclutamento
- Chongqing University Cancer Hospital
-
Guangzhou, Cina, 510120
- Reclutamento
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Cina, 510060
- Reclutamento
- Sun Yat Sen University Cancer Center
-
Hangzhou, Cina, 310009
- Reclutamento
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanjing, Cina, 210009
- Reclutamento
- Nanjing Drum Tower Hospital
-
Shanghai, Cina, 200080
- Reclutamento
- Shanghai General Hospital
-
Shanghai, Cina, 200031
- Reclutamento
- Huashan Hospital Fudan University
-
Shanghai, Cina, 200082
- Reclutamento
- Xinhua hospital,Shanghai Jiaotong University
-
Tianjin, Cina, 300211
- Reclutamento
- The Second Hospital Of Tianjin Medical University
-
Wuhan, Cina, 430014
- Reclutamento
- The Central Hospital of Wuhan
-
Xi'an, Cina, 710061
- Reclutamento
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Goyang-si, Corea del Sud, 10408
- Reclutamento
- National Cancer Center
-
Seoul, Corea del Sud, 05505
- Reclutamento
- Asan Medical Center
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
Seoul, Corea del Sud, 03722
- Reclutamento
- Severance Hospital Yonsei University Health System
-
Seoul, Corea del Sud, 06591
- Reclutamento
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Bordeaux, Francia, 33076
- Reclutamento
- Institut Bergonie
-
Clermont-Ferrand, Francia, 63011
- Reclutamento
- Centre Jean Perrin
-
Lille, Francia, 59000
- Reclutamento
- Centre Oscar Lambret
-
Lyon, Francia, 69008
- Reclutamento
- Centre Leon Berard
-
Nîmes, Francia, 30900
- Reclutamento
- Groupe Hospitalo-Universitaire Carémeau
-
Paris, Francia, 75908
- Reclutamento
- Hopital Europeen Georges-Pompidou
-
Rennes, Francia, 35062
- Reclutamento
- Centre Eugene Marquis
-
Villejuif, Francia, 94800
- Reclutamento
- Gustave Roussy
-
-
-
-
-
Dresden, Germania, 01307
- Reclutamento
- Universitatsklinikum Carl Gustav Carus Dresden
-
Duisburg, Germania, 47169
- Reclutamento
- Urologicum Duisburg
-
Essen, Germania, 45147
- Reclutamento
- Universitaetsklinikum Essen
-
Hamburg, Germania, 20246
- Reclutamento
- Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf Urologie
-
München, Germania, 81675
- Reclutamento
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Nürtingen, Germania, 72622
- Reclutamento
- Studienpraxis Urologie Drs. Feyerabend
-
-
-
-
-
Bunkyō City, Giappone, 113 8431
- Reclutamento
- Juntendo University Hospital
-
Hirakata, Giappone, 573-1191
- Reclutamento
- Kansai Medical University Hospital
-
Kanazawa, Giappone, 920 8641
- Reclutamento
- Kanazawa University Hospital
-
Kobe, Giappone, 650 0017
- Reclutamento
- Kobe University Hospital
-
Sagamihara, Giappone, 252-0375
- Reclutamento
- Kitasato University Hospital
-
Sunto Gun, Giappone, 411 8777
- Reclutamento
- Shizuoka Cancer Center
-
Yokohama, Giappone, 232 0024
- Reclutamento
- Yokohama City University Medical Center
-
-
-
-
-
Florence, Italia, 50134
- Reclutamento
- Azienda Ospedaliero Universitaria Careggi
-
Localita La Schiana Pozzuoli, Italia, 80078
- Reclutamento
- ASL Napoli 2 Nord-SM delle Grazie Hospital
-
Milan, Italia, 20141
- Reclutamento
- Istituto Europeo di Oncologia
-
Milan, Italia, 20132
- Reclutamento
- IRCCS Ospedale San Raffaele
-
Roma, Italia, 00144
- Reclutamento
- Istituto Nazionale Tumori Regina Elena
-
Torino, Italia, 10126
- Reclutamento
- Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino
-
-
-
-
-
Kota Kinabalu, Malaysia, 88996
- Reclutamento
- Hospital Wanita dan Kanak-Kanak Sabah
-
Kuala Lumpur, Malaysia, 59100
- Reclutamento
- University Malaya Medical Centre
-
Kuala Lumpur, Malaysia, 50586
- Reclutamento
- Hospital Kuala Lumpur
-
Kuala Lumpur, Malaysia, 59100
- Reclutamento
- Pantai Hospital Kuala Lumpur
-
Kuching, Malaysia, 93586
- Reclutamento
- Hospital Umum Sarawak
-
-
-
-
-
San Juan, Porto Rico, 935
- Reclutamento
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Cardiff, Regno Unito, CF14 2TL
- Reclutamento
- Velindre Cancer Centre
-
Glasgow, Regno Unito, G12 0YN
- Reclutamento
- Beatson West Of Scotland Cancer Centre
-
London, Regno Unito, EC1A 7BE
- Reclutamento
- St Bartholomews Hospital
-
London, Regno Unito, SW3 6JJ
- Reclutamento
- The Royal Marsden NHS Trust
-
Newcastle upon Tyne, Regno Unito, NE7 7DN
- Reclutamento
- The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
-
Preston, Regno Unito, PR2 9HT
- Reclutamento
- Lancashire Teaching Hospitals NHS Foundation Trust Royal Preston Hospital
-
Sutton, Regno Unito, SM2 5PT
- Reclutamento
- Royal Marsden Hospital
-
-
-
-
-
Badalona, Spagna, 08916
- Reclutamento
- Hosp. Univ. Germans Trias I Pujol
-
Madrid, Spagna, 28034
- Reclutamento
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Spagna, 28041
- Reclutamento
- Hosp. Univ. 12 de Octubre
-
Murcia, Spagna, 30008
- Reclutamento
- Hosp. Gral. Univ. J.M. Morales Meseguer
-
Seville, Spagna, 41009
- Reclutamento
- Hosp. Virgen Macarena
-
Valencia, Spagna, 46014
- Reclutamento
- Hosp. Gral. Univ. Valencia
-
Zaragoza, Spagna, 50009
- Reclutamento
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
Arizona
-
Chandler, Arizona, Stati Uniti, 85225
- Reclutamento
- Arizona Clinical Trials
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72211
- Reclutamento
- Arkansas Urology
-
Springdale, Arkansas, Stati Uniti, 72762
- Reclutamento
- Highlands Oncology Group
-
-
California
-
Fountain Valley, California, Stati Uniti, 92708
- Reclutamento
- MemorialCare Orange Coast Medical Center
-
La Jolla, California, Stati Uniti, 92037
- Reclutamento
- University Of California San Diego
-
Los Alamitos, California, Stati Uniti, 90720
- Reclutamento
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Stati Uniti, 90033
- Reclutamento
- USC Norris Comprehensive Cancer Center
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- Ronald Reagan UCLA Medical Center
-
Los Angeles, California, Stati Uniti, 90067
- Reclutamento
- Valkyrie Clinical Trials
-
Riverside, California, Stati Uniti, 92505
- Reclutamento
- Kaiser Permanente Southern California
-
San Diego, California, Stati Uniti, 92123
- Reclutamento
- Sharp Center for Research
-
Santa Monica, California, Stati Uniti, 90404
- Reclutamento
- Providence Saint John s Health Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80012
- Reclutamento
- Rocky Mountain Cancer Centers
-
Denver, Colorado, Stati Uniti, 80210
- Reclutamento
- AdventHealth Porter Oncology Research
-
Edwards, Colorado, Stati Uniti, 81632
- Reclutamento
- Vail Health Shaw Cancer Center
-
Grand Junction, Colorado, Stati Uniti, 81505
- Reclutamento
- Grand Valley Oncology
-
Lakewood, Colorado, Stati Uniti, 80228
- Reclutamento
- Colorado Clinical Research
-
-
Florida
-
Orlando, Florida, Stati Uniti, 32803
- Reclutamento
- AdventHealth Orlando
-
Pembroke Pines, Florida, Stati Uniti, 33026
- Reclutamento
- Memorial Cancer Institute
-
Sarasota, Florida, Stati Uniti, 34232
- Reclutamento
- Florida Cancer Specialists
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Winship Cancer Institute Emory University
-
-
Illinois
-
Lisle, Illinois, Stati Uniti, 60532
- Reclutamento
- Duly Health and Care
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67214
- Reclutamento
- Cancer Center of Kansas Heritage Plaza Medical Building
-
-
Kentucky
-
Edgewood, Kentucky, Stati Uniti, 41017
- Reclutamento
- St Elizabeth Healthcare
-
Louisville, Kentucky, Stati Uniti, 40207
- Reclutamento
- Norton Cancer Institute
-
-
Louisiana
-
Metairie, Louisiana, Stati Uniti, 70006
- Reclutamento
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins Hospital
-
Baltimore, Maryland, Stati Uniti, 21201
- Reclutamento
- University of Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins Medical Institutions
-
Bethesda, Maryland, Stati Uniti, 20817
- Reclutamento
- Center for Cancer and Blood Disorders
-
Towson, Maryland, Stati Uniti, 21204
- Reclutamento
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General
-
-
Michigan
-
Sterling Heights, Michigan, Stati Uniti, 48314
- Reclutamento
- Profound Research LLC at Cancer and Leukemia Center
-
-
Minnesota
-
Saint Louis Park, Minnesota, Stati Uniti, 55426
- Reclutamento
- HealthPartners Frauenshuh Cancer Center CRC West
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Reclutamento
- HealthPartners Cancer Center at Regions Hospital CRC East
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- Reclutamento
- University of Mississippi Medical Center
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University
-
-
Nebraska
-
Lincoln, Nebraska, Stati Uniti, 68506
- Reclutamento
- NHO Revive Research Institute, LLC
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Reclutamento
- Cooper Health System MD Anderson Cancer Center at Cooper
-
East Brunswick, New Jersey, Stati Uniti, 08816
- Reclutamento
- Astera Cancer Care
-
New Brunswick, New Jersey, Stati Uniti, 08901
- Reclutamento
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Mineola, New York, Stati Uniti, 11501
- Reclutamento
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
The Bronx, New York, Stati Uniti, 10461
- Reclutamento
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
-
Ohio
-
Canton, Ohio, Stati Uniti, 44718
- Reclutamento
- Gabrail Cancer Center
-
Cincinnati, Ohio, Stati Uniti, 45219
- Reclutamento
- University of Cincinnati
-
Cleveland, Ohio, Stati Uniti, 44109
- Reclutamento
- Metrohealth Medical Center
-
-
Oregon
-
Springfield, Oregon, Stati Uniti, 97477
- Reclutamento
- Oregon Urology Institute
-
-
Pennsylvania
-
Allentown, Pennsylvania, Stati Uniti, 18103
- Reclutamento
- Lehigh Valley Hospital
-
Bala-Cynwyd, Pennsylvania, Stati Uniti, 19004
- Reclutamento
- MidLantic Urology
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Reclutamento
- Penn State Milton S. Hershey Medical Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Reclutamento
- Carolina Urologic Research Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Reclutamento
- Avera Medical Group
-
Watertown, South Dakota, Stati Uniti, 57201
- Reclutamento
- Prairie Lakes Health Care System
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37909
- Reclutamento
- Tennessee Cancer Specialists
-
-
Texas
-
Austin, Texas, Stati Uniti, 78731
- Reclutamento
- Texas Oncology
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- UT Southwestern Medical Center
-
Houston, Texas, Stati Uniti, 77027
- Reclutamento
- Houston Metro Urology
-
Sugar Land, Texas, Stati Uniti, 77479
- Reclutamento
- Texas Oncology 1
-
The Woodlands, Texas, Stati Uniti, 77380
- Reclutamento
- Renovatio Clinical
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Virginia Cancer Specialists
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Fred Hutch Cancer Center Sloan Clinic 2
-
-
-
-
-
Taichung, Taiwan, 435
- Reclutamento
- Tungs' Taichung MetroHarbor Hospital
-
Taichung, Taiwan, 404
- Reclutamento
- China Medical University Hospital
-
Taichung, Taiwan, 407219
- Reclutamento
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- Reclutamento
- National Cheng Kung University Hospital
-
Taoyuan, Taiwan, 333
- Reclutamento
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Adana, Turchia (Türkiye), 01170
- Reclutamento
- Adana City Hospital
-
Ankara, Turchia (Türkiye), 06010
- Reclutamento
- Gulhane Training and Research Hospital
-
Ankara, Turchia (Türkiye), 06100
- Reclutamento
- Ankara University Medical Faculty
-
Istanbul, Turchia (Türkiye), 34096
- Reclutamento
- Istanbul University Cerrahpasa tip Fakultesi
-
Istanbul, Turchia (Türkiye), 34147
- Reclutamento
- Koc Universitesi Hastanesi
-
Izmir, Turchia (Türkiye), 35170
- Reclutamento
- Medicana International Izmir
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
- Have histologically confirmed adenocarcinoma of the prostate
- Have disease that is metastatic at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m^Tc bone scan as determined by the investigator
- Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening
- Have progressed by PSA or CT/MRI or 99m^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
Exclusion criteria:
- Known history of either brain or leptomeningeal prostate cancer metastases
- Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated
- Prior or concurrent second malignancy (other than the disease under study)
- Received cytotoxic chemotherapy for prostate cancer in any setting
- Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Pasritamig+Docetaxel
Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met. |
Pasritamig will be administered.
Altri nomi:
Docetaxel will be administered. |
|
Comparatore attivo: Docetaxel
Participants will receive docetaxel along with prednisone/prednisolone as background medication. |
Docetaxel will be administered. Prednisone/Prednisolone will be administered. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)
Lasso di tempo: Up to approximately 1 years 10 months
|
rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first. |
Up to approximately 1 years 10 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: Up to approximately 4 years 5 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 4 years 5 months
|
|
Time to Symptomatic Progression (TSP)
Lasso di tempo: Up to approximately 4 years 5 months
|
TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation to relieve cancer-related symptoms, the need for tumor-related surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms. |
Up to approximately 4 years 5 months
|
|
Time to Subsequent Therapy (TST)
Lasso di tempo: Up to approximately 4 years 5 months
|
TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy for prostate cancer |
Up to approximately 4 years 5 months
|
|
Time to Skeletal-Related Event (TSRE)
Lasso di tempo: Up to approximately 4 years 5 months
|
TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression. |
Up to approximately 4 years 5 months
|
|
Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 4 years 5 months
|
ORR is defined as the proportion of participants who have measurable disease at baseline and have complete response (CR) or partial response (PR) or better by objective radiographic disease evaluation per response evaluation criteria in solid tumors (RECIST) version.1.1 response criteria and no bone progression as per prostate cancer working group 3 (PCWG3) as determined by the BICR. |
Up to approximately 4 years 5 months
|
|
Duration of Response (DOR)
Lasso di tempo: Up to approximately 4 years 5 months
|
DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first. |
Up to approximately 4 years 5 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
Lasso di tempo: Up to approximately 4 years 5 months
|
Time to PSA progression is defined as the time from randomization to the first date of documented PSA progression per prostate cancer working group 3 (PCWG3) criteria. PSA progression is defined as: (1) After a decline from baseline, PSA increases greater than or equal to (>=) 25% and >=2 nanogram per milliliter (ng/mL) above the nadir, confirmed by a second value >=3 weeks later (that is, a confirmed rising trend), or (2) If there is no decline from baseline, PSA increases >=25% and >=2 ng/mL from baseline after 12 weeks |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 50 Response
Lasso di tempo: Up to approximately 4 years 5 months
|
PSA-50 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 50% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 90 Response
Lasso di tempo: Up to approximately 4 years 5 months
|
PSA-90 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 90% from baseline, confirmed by a second value, at least 3 weeks apart. |
Up to approximately 4 years 5 months
|
|
Duration of PSA Response
Lasso di tempo: Baseline and up to approximately 4 years 5 months
|
Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from baseline by >= 50%. |
Baseline and up to approximately 4 years 5 months
|
|
Progression Free Survival After Subsequent Therapy (PFS2)
Lasso di tempo: Up to approximately 4 years 5 months
|
PFS2 is defined as the time from randomization to the date of progression (radiographic, clinical, or PSA progression) on the first subsequent anti-cancer (second progression), or death from any cause, whichever comes first. |
Up to approximately 4 years 5 months
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity
Lasso di tempo: Up to approximately 4 years 5 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE: results in death, is life-threatening, requires inpatient hospitalization or prolonging hospitalization, results in disability, is a congenital birth defect, is a suspected transmission of any infectious agent via a medicinal product, is indicating suicidal ideation, is medically important. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 4 years 5 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
Lasso di tempo: Up to approximately 4 years 5 months
|
Participants with laboratory abnormalities (hematology, serum chemistry, coagulation, and tumor markers) will be reported. |
Up to approximately 4 years 5 months
|
|
Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
Lasso di tempo: Baseline up to approximately 4 years 5 months
|
The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer Module (EORTC QLQ-C30) Scale Score
Lasso di tempo: Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-C30 - Version 3 is a self-administered, 30-item questionnaire measuring the health-related quality of life of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by EORTC Quality of Life Questionnaire-Prostate (EORTC QLQ-PR25) Scale Score
Lasso di tempo: Baseline up to approximately 4 years 5 months
|
The EORTC QLQ-PR25 is a self-completed instrument was specifically designed for prostate cancer patients and includes 25 items that cover 6 dimensions: (1) PR URI (urinary symptoms, 8 items), (2) PR BOW (bowel symptoms, 4 items), (3) PR HTR (hormonal treatment-related symptoms, 6 items), (4) PR AID (incontinence aid, 1 item), (5) PR SAC (sexually active, 2 items); and (6) PR SFU (sexual function, 4 items). Higher scores on symptom domains (for example., urinary, bowel, etc.) indicate greater symptom burden and higher scores on function domains (for example, Sexual Function) indicate better functioning. |
Baseline up to approximately 4 years 5 months
|
|
Change from Baseline in HRQoL as Assessed by European Quality of Life Visual Analog Scale (EQ-5D VAS) Score
Lasso di tempo: Baseline up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Here, higher score indicates better quality of life. |
Baseline up to approximately 4 years 5 months
|
|
Time to Sustained Worsening of Pain as Assessed by BPI-SF
Lasso di tempo: Up to approximately 4 years 5 months
|
Time to sustained worsening of pain will be reported using BPI-SF. The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain. |
Up to approximately 4 years 5 months
|
|
Treatment Side Effect as Assessed by EORTC IL46 Score
Lasso di tempo: Up to approximately 4 years 5 months
|
The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much". |
Up to approximately 4 years 5 months
|
|
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Scale Score
Lasso di tempo: Up to approximately 4 years 5 months
|
The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "No problems" to "Extreme problems". Here, higher score indicates better quality of life. |
Up to approximately 4 years 5 months
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Neoplasie genitali, maschio
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie genitali, maschio
- Malattie della prostata
- Malattie urogenitali maschili
- Neoplasie prostatiche
- Neoplasie prostatiche resistenti alla castrazione
- Prodotti chimici organici
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Composti policiclici
- Taxoidi
- Ciclodecani
- Diterpenes
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Incintadienetrioli
- Incintadienediols
- Docetaxel
- Prednisone
- Prednisolone
Altri numeri di identificazione dello studio
- 78278343PCR3003
- 2025-522713-29-00 (Identificatore di registro: EUCT number)
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .